#AskDrDurie

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Mar
15
What impact do Revlimid® (lenalidomide) and Pomalyst® (pomalidomide) have on the bone marrow?
In this week’s video, Brian G.M. Durie explains that even though Revlimid and Pomalyst may reduce white blood cell counts, they do not permanently affect the bone marrow.
Mar
08
What supplements, if any, should a myeloma patient take?
In this week’s video, Dr. Brian G.M. Durie explains that supplements might have side effects or might interfere with medications for myeloma.
Mar
01
What should patients do if their doctor is unsure if they have smoldering or active myeloma?
In this week’s video, Dr. Brian G.M. Durie emphasizes the importance of correctly diagnosing and staging myeloma before beginning treatment for the disease. BOTTOM LINE: ​ Seek out a myeloma expert(...)
Feb
22
What are the options for a myeloma patient who has relapsed on a two-drug combination?
In this week’s video, Dr. Brian G.M. Durie advises that patients discuss with their doctors the many aspects of various treatments, including possible toxicities, cost issues, the patient’s overall(...)
Feb
15
Should patients with light chain myeloma be more wary of disease outcomes than those with other types of myeloma?
In this week’s video, Dr. Brian G.M. Durie explains that the underlying biology of light chain myeloma is very similar to IgG or IgA myeloma.
Feb
08
How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ?
In this week’s video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma — the CESAR trial and the CENTAURUS trial. BOTTOM LINE: The IMF’s Black Swan Research(...)